Moderna (MRNA) Stock Price and Forecast: Why do dead cats bounce?
- MRNA shares slump on Tuesday after a strong bounce on Monday.
- FXStreet had called the Monday bounce as likely to fail.
- Moderna needs to find a new revenue source as covid likely to fade.
Moderna (MRNA) shares failed to rally on Tuesday despite Fed Chair Powell talking calmly to Capitol Hill and soothing most equities in the process. Risk was back on and rate hikes are also likely on, this time in March. Powell has carefully mapped out the strategy so as not to surprise markets, and despite yields rising slightly, tech continued to bounce on Tuesday. However, Moderna shares slumped.
Moderna (MRNA) stock news
Shares in Moderna closed over 5% lower at $221.39 on Tuesday. Many traders are asking why, when all major indices closed higher. Mainstream media have been trotting out the rotation line, which is a neat excuse for, "We don't really know why that happened, so let us just compare it to something else."
The fact as always is to do with momentum and trends. Moderna has been falling, and this latest fall is symptomatic of waning investor interest as covid looks to fade. Moderna is hugely over-reliant on its covid vaccine for income. Yes, it has a decent pipeline, but nothing else can come close to matching the revenue generation of its covid vaccine. This is the big problem.
Pfizer is much more diversified and a larger company with multiple revenue streams. Moderna (MRNA) is not in this league. It may get there one day, but in the meantime it will face revenue generation challenges. Take a look at the Moderna development pipeline here. It is impressive but nothing that looks either imminent or significant in terms of replacing covid vaccine revenue. Covid is/was a once-in-a-century event (fingers crossed).
Moderna (MRNA) stock forecast
There is nothing significant in Monday's move despite MRNA shares closing 9% higher. We outlined this in our article earlier in the week and remain bearish on Moderna. The trend is in place as Monday failed to break above $259, so we remain with lower lows and lower highs. $259 is the pivot for the short term. $188.41 is the first target with $200 a big psychological level along the way. There is a pattern here: declining Relative Strength Index (RSI), declining Moving Average Convergence Divergence (MACD) and declining stock price. We have a volume gap from $200 until $180. There is more downside in our view unless MRNA shares close above $259.
Moderna (MRNA) chart, daily
Like this article? Help us with some feedback by answering this survey:
Premium
You have reached your limit of 3 free articles for this month.
Start your subscription and get access to all our original articles.
Author
Ivan Brian
FXStreet
Ivan Brian started his career with AIB Bank in corporate finance and then worked for seven years at Baxter. He started as a macro analyst before becoming Head of Research and then CFO.
